Welcome to our dedicated page for Talphera news (Ticker: TLPH), a resource for investors and traders seeking the latest updates and insights on Talphera stock.
Talphera, Inc. reports news centered on its specialty pharmaceutical development business, with recurring updates on Niyad, nafamostat research, continuous renal replacement therapy and medically supervised care settings. Company announcements commonly cover financial results, corporate updates, clinical-study developments, research presentations and regulatory designations tied to the Niyad program.
Other recurring Talphera news includes financings involving common stock and pre-funded warrants, board and governance changes, investor events and business updates related to its development-stage pharmaceutical portfolio.
Talphera (TLPH)/b) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, at 4:30 p.m. ET in New York, NY.The session will feature a fireside chat and 1x1 meetings with CEO Vince Angotti and Chief Medical Officer Shakil Aslam, MD. A webcast and 90-day replay will be available via Talphera’s investor website.
Talphera (Nasdaq: TLPH) reported second quarter 2026 results and a corporate update on nafamostat. The NEPHRO CRRT registrational study of lead candidate Niyad reached 75% enrollment and is expected to complete this year, with all target clinical sites now activated.
Draft 2026 KDIGO acute kidney guidelines, after public comment, cited nafamostat as an acceptable CRRT anticoagulant, a change from prior recommendations. Updated market research estimates about 200,000 U.S. CRRT procedures in 2027, a 21% increase over Talphera’s prior estimate. The company regained Nasdaq $1 bid-price compliance.
For Q2 2026, cash and investments were $17.1 million. Combined R&D and SG&A expenses were $3.9 million, up from $3.7 million a year earlier. Net loss attributable to common shareholders was $4.3 million, or $0.06 per share, versus $3.5 million, or $0.10 per share, in Q2 2025.
Talphera (Nasdaq: TLPH) will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m. ET / 1:30 p.m. PT to discuss its second quarter 2026 financial results and recent business progress. North American participants can dial 1-800-836-8184 and international participants 1-646-357-8785 using conference ID 50873. A live webcast and a 90-day replay will be available via the Upcoming Events page in the Investors section of the Talphera website.
Talphera (Nasdaq:TLPH) reported first quarter 2026 results and a clinical update. The NEPHRO CRRT nafamostat study surpassed 50% enrollment and is expected to complete in 2026. In March, Talphera closed a $4.1 million tranche tied to enrollment milestones.
As of March 31, 2026, cash and investments totaled $21.1 million. Combined R&D and SG&A expenses were $3.9 million, up from $2.9 million a year earlier. Net loss attributable to common shareholders was $2.6 million, or $0.04 per share, unchanged in dollar terms from 2025 but with a lower loss per share.
Talphera (Nasdaq: TLPH) will release Q1 2026 financial results after market close on Wednesday, May 13, 2026, followed by a live webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT.
The webcast includes a slide presentation; a replay will be available on the Talphera investor website for 90 days. Dial-in details and conference ID 24180 are provided for live participation.
Talphera (Nasdaq: TLPH) announced two abstracts accepted for presentation at AKI & CRRT 2026 (March 29–April 2, 2026) describing nafamostat as a regional anticoagulant for CRRT. One poster details the ongoing registrational NEPHRO-CRRT trial now enrolling patients; the other reports porcine PK/PD data showing >95% pre-filter removal and minimal systemic ACT effect.
The company says a target post-filter ACT of 175–225 seconds may provide extracorporeal anticoagulation while limiting systemic effects; if approved, nafamostat would be the first FDA-approved regional anticoagulant for CRRT.
Talphera (Nasdaq: TLPH) reported Q4 and full‑year 2025 results and a corporate update on March 23, 2026. Key items: 50% enrollment (35 of 70) in the NEPHRO CRRT registrational study, closing of a $4.1M financing tranche, and $20.4M cash and investments at December 31, 2025.
Q4 combined R&D and SG&A were $3.5M, net loss attributable to common shareholders was $3.8M (or $0.06 per share). 2026 cash operating expenses are guided to $17–18M. A virtual investor day was held March 23, 2026.
Talphera (Nasdaq: TLPH) will host a virtual investor and analyst event on March 23, 2026 at 11:00 AM ET to discuss Niyad for use in continuous renal replacement therapy (CRRT).
Presenters Blaithin McMahon, PhD, MBBChr, and Joao Teixeira, MD, principal investigators in the NEPHRO CRRT study, will review CRRT anticoagulation practices, nafamostat's profile, and a live Q&A will follow.
Talphera (Nasdaq: TLPH) announced it has enrolled 35 of 70 patients (50%) in the NEPHRO-CRRT registrational trial as of March 2, 2026. The company said it reduced total enrollment by nearly 60%, refocused sites on medical ICUs with nephrologist PIs, and achieved >90% enrollment from new sites.
Talphera will host a virtual investor and analyst event on March 23, 2026 at 11:00 am ET featuring nephrologists Dr. Blaithin McMahon and Dr. Joao Teixeira; a replay will be available for 90 days.
Talphera (Nasdaq: TLPH) reported third quarter 2025 results and a corporate update on November 12, 2025. Key items: Talphera closed a $17.0 million first tranche of a potential $29.0 million private placement led by CorMedix (Nasdaq: CRMD); cash and investments were $21.3 million at September 30, 2025. Five of nine target NEPHRO CRRT study sites are active and study completion is expected in H1 2026. Q3 combined R&D and SG&A were $3.4 million (ex-stock comp $3.3M). Q3 net loss from continuing operations was $4.4 million ($0.11 per share). 2025 cash operating expense guidance was reduced to $14–15 million.